EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target

Hareesh B Nair, Ajay Nair, Ya-Guang Liu, Dileep K Vijayan, Ramadevi Subramani, Rajkumar Lakshmanaswamy, Suryavathi Viswanadhapalli, Gangadhara R Sareddy, Surinder K Batra, Ratna K Vadlamudi

Cancer Letters · 2026-03 · 641 · 218258

DOI: 10.1016/j.canlet.2026.218258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026-03. Verfasst von Hareesh B Nair und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Translational Medicine, Texas Tech University Health Science Center, El Paso, TX, 79905, USA. Electronic address: hbhaska…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Midkine, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BLRD VA, NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Midkine (MDK) is an oncofetal, heparin-binding cytokine that is re-expressed across diverse cancers and correlates with aggressive disease and treatment resistance. This review synthesizes current evidence on MDK as a coordinator of tumor-intrinsic signaling and microenvironmental remodeling. We summarize MDK structural features, extracellular matrix interactions, and receptor systems that mediate MDK signaling, highlighting LRP1 and PTPRZ1 with context-dependent participation of ALK, nucleolin and integrins. Downstream, MDK engages MAPK, PI3K-AKT, STAT3 and NF-κB pathways to promote tumor cell survival, epithelial-mesenchymal plasticity, and therapeutic stress tolerance. We then focus on tumor microenvironment (TME) programs shaped by MDK, including angiogenesis, fibroblast activation and extracellular matrix remodeling, and the establishment of immunosuppressive niches. Across tumor types, MDK is linked to impaired dendritic-cell function, polarization of tumor-associated macrophages, accrual of myeloid-derived suppressor cells and reduced CD8+ T-cell cytotoxic fitness. Finally, we review translational opportunities and challenges, including candidate biomarkers (tumor MDK by IHC/RNA and circulating MDK by ELISA) and rational combination strategies that pair MDK blockade with MAPK-pathway inhibitors or PD-1/PD-L1 immunotherapy. Collectively, these data position MDK as a tractable node connecting tumor-intrinsic signaling with stromal and immune regulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentMidkineNeoplasmsHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

AngiogenesisBiomarkersCancer-associated fibroblastsHematologic malignanciesImmune evasionImmunotherapyLigand-receptor interactionsMDKSingle cell transcriptomicsSolid tumorsTMETumor immune suppression

Substanzen

MidkineMDK protein, human

Autor:innen und Institutionen

  • Department of Molecular and Translational Medicine, Texas Tech University Health Science Center, El Paso, TX, 79905, USA. Electronic address: hbhaskar@ttuhsc.edu.
  • School of Medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, 682041, India.
  • Department of Pathology and Laboratory Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.
  • Laboratory for Computational and Structural Biology, Jubilee Centre for Medical Research, Thrissur, India.
  • Department of Molecular and Translational Medicine, Texas Tech University Health Science Center, El Paso, TX, 79905, USA.
  • Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX, USA.

Förderung

  • BLRD VA
  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • US Department of Veterans Affairs
  • Texas Tech University Health Sciences Center El Paso Paul L Foster School of Medicine
  • Harvard Transdisciplinary Research in Energetics and Cancer Center, Harvard University
  • National Cancer Center
  • Cancer Prevention and Research Institute of Texas

Zitieren

APA

Nair, H. B., Nair, A., Liu, Y. G., Vijayan, D. K., Subramani, R., Lakshmanaswamy, R., Viswanadhapalli, S., Sareddy, G. R., Batra, S. K., & Vadlamudi, R. K. (2026). Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target. Cancer Letters, 641, 218258. https://doi.org/10.1016/j.canlet.2026.218258

Vancouver

Nair HB, Nair A, Liu YG, Vijayan DK, Subramani R, Lakshmanaswamy R, et al. Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target. Cancer Letters. 2026;641:218258. doi:10.1016/j.canlet.2026.218258

BibTeX
@article{Nair2026,
  author = {Nair, Hareesh B and Nair, Ajay and Liu, Ya-Guang and Vijayan, Dileep K and Subramani, Ramadevi and Lakshmanaswamy, Rajkumar and Viswanadhapalli, Suryavathi and Sareddy, Gangadhara R and Batra, Surinder K and Vadlamudi, Ratna K},
  title = {Midkine (MDK) as a central regulator of the tumor microenvironment: From developmental cytokine to therapeutic target},
  journal = {Cancer Letters},
  year = {2026},
  volume = {641},
  pages = {218258},
  doi = {10.1016/j.canlet.2026.218258}
}
Kostenlos starten →